Piper Jaffray Cos. set a $447.00 target price on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research report report published on Thursday morning. The firm currently has a a hold rating on the biopharmaceutical company’s stock.
REGN has been the subject of several other reports. Cowen and Company restated a hold rating and issued a $430.00 price target on shares of Regeneron Pharmaceuticals in a report on Friday, August 5th. Roth Capital reiterated a buy rating and set a $520.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, September 23rd. Citigroup Inc. reiterated a buy rating and set a $470.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 23rd. Vetr downgraded Regeneron Pharmaceuticals from a buy rating to a hold rating and set a $422.08 price objective for the company. in a report on Wednesday, July 27th. Finally, Canaccord Genuity reiterated a hold rating and set a $450.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, June 17th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of Hold and an average target price of $480.09.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 366.73 on Thursday. The firm has a market capitalization of $38.37 billion, a price-to-earnings ratio of 57.21 and a beta of 1.31. Regeneron Pharmaceuticals has a 12-month low of $329.09 and a 12-month high of $592.59. The company has a 50-day moving average price of $396.54 and a 200 day moving average price of $392.52.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.17. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. The firm had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the prior year, the firm posted $2.89 earnings per share. The company’s quarterly revenue was up 21.4% on a year-over-year basis. Equities research analysts expect that Regeneron Pharmaceuticals will post $11.02 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,125 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $425.00, for a total transaction of $903,125.00. Following the transaction, the director now directly owns 15,125 shares of the company’s stock, valued at approximately $6,428,125. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.40% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP increased its position in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock valued at $2,239,195,000 after buying an additional 1,426,801 shares during the last quarter. Winslow Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $291,760,000. FMR LLC increased its position in shares of Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock valued at $3,288,642,000 after buying an additional 795,283 shares during the last quarter. Capital World Investors increased its position in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock valued at $2,558,678,000 after buying an additional 312,008 shares during the last quarter. Finally, Emerald Acquisition Ltd. bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $87,319,000. 68.32% of the stock is currently owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.